Order Article Reprints

Lema L, Pérez-García JM, Blanch S, Balmaña J, García-Sáenz JÁ, Vegas EF, Jiménez B, de la Haba J, Campolier M, Shimizu E, et al. Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation. Cancers. 2025; 17(11):1744. https://doi.org/10.3390/cancers17111744

Lema, Laura, José Manuel Pérez-García, Salvador Blanch, Judith Balmaña, José Ángel García-Sáenz, Elena Filipovich Vegas, Begoña Jiménez, Juan de la Haba, Marta Campolier, Eileen Shimizu, and et al. 2025. "Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation" Cancers 17, no. 11: 1744. https://doi.org/10.3390/cancers17111744

Lema, L., Pérez-García, J. M., Blanch, S., Balmaña, J., García-Sáenz, J. Á., Vegas, E. F., Jiménez, B., de la Haba, J., Campolier, M., Shimizu, E., Alcalá-López, D., Sampayo-Cordero, M., Cortés, J., & Llombart-Cussac, A. (2025). Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation. Cancers, 17(11), 1744. https://doi.org/10.3390/cancers17111744